Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ibuprofen in children

This article was originally published in The Tan Sheet

Executive Summary

Adverse events in children taking either ibuprofen or acetaminophen are "rare and generally <1% for both treatments" in subjects under two and two to 18, according to an abstract of a study sponsored by Children's Advil maker Whitehall-Robins. The study is to be published in the Journal of Inflammopharmacology. The AEs include abdominal pain, insomnia and hyperkinesia. The Children's Analgesic Medicine Project (CAMP) was an open-label study comparing the safety of ibuprofen suspension with acetaminophen in 41,810 children ages one to 18 with fever and/or pain. "There was a slightly higher overall incidence of side effects in the ibuprofen group (17.6% v. 15%) for the younger children; and 11.9% v. 10.7% for the older children," the abstract says. The data were presented at the Whitehall-sponsored International Conference on Inflammopharmacology in Braselton, Ga. May 23-26

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel